Characteristics of obesity and glycolipid metabolism in polycystic ovary syndrome patients with diminished ovarian reserve

doi:10.3969/j.issn.1006-7795.2018.04.005

Abstract

Abstract: Objective To explore the characteristics of obesity and glycolipid metabolism in polycystic ovary syndrome (PCOS) patients with diminished ovarian reserve (DOR). Methods Totally 338 PCOS patients (including 57 PCOS with DOR patients and 281 simple PCOS patients) and 70 healthy women (control group), who came to Department of Gynecological Endocrinology in Beijing Obstetrics and Gynecology Hospital between January 2015 and January 2017, were recruited. Age and menstruation of these patients were recorded. Body height, body weight, waist circumference, hip circumference, basel follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E₂), testosterone (T), anti-Müllerian hormone (AMH), fasting plasma glucose (FPG), fasting insulin (FINS), total cholesterol (TC), triglyceride (TG), high density lipoprotein-cholesterol (HDL-C), low density and lipoprotein-cholesterol (LDL-C) and baseline antral follicle count of these patients were measured. The indices between PCOS with DOR, simple PCOS and control group were compared, and the correlations between AMH and other indices in each group were analyzed. Results (1) The prevalence of central obesity (≥ 25 kg/m²) in simple PCOS, PCOS with DOR and control group was 38.1%, 40.4% and 22.9%, respectively. And the prevalence of abdominal obesity waist hip ratio (WHR) ≥ 0.85 in simple PCOS, PCOS with DOR and control group was 46.6%, 21.1% and 28.6%, respectively. The prevalence of central obesity in PCOS with DOR patients had no significant difference with simple PCOS patients and control group (P>0.05), but the prevalence of abdominal obesity was lower than simple PCOS patients (P<0.05). (2) The level of FPG, FINS and homeostasis model assessment (HOMA)-insulin resistivity (IR) in PCOS with DOR patients had no significant differences from simple PCOS patients(P>0.05), while the level of FPG and HOMA-IR was higher than control group (P<0.05). (3) The levels of TC, HDL-C and LDL-C in both simple PCOS and PCOS with DOR patients were higher than control group (P<0.05). The levels of TC, triglyceride (TG), HDL-C and LDL-C in PCOS with DOR patients had no significant difference with simple PCOS patients (P<0.05). (4) In simple PCOS patients, AMH had a negative correlation with FPG and HOMA-IR (P<0.05), while had a positive correlation with HDL-C (P<0.01). In PCOS with DOR patients, AMH had no correlation with obesity and glycolipid metabolic indices (P>0.05). In control group, AMH had a positive correlation with HDL-C (P<0.01). Conclusion The prevalence of abdominal obesity in PCOS with DOR patients is lower than simple PCOS patients. The characteristic of glycolipid metabolism in PCOS with DOR patients is similar to simple PCOS patients. But the correlation between AMH and glycolipid metabolic indices in PCOS with DOR patients is different from both simple PCOS patients and control group.

Key words: polycystic ovary syndrome, diminished ovarian reserve, anti-Müllerian hormone, obesity, insulin resistance

CLC Number:

R711.77

Jin Jing, Ruan Xiangyan, Hua Lin, Li Yanglu, Wang Lijuan, Wang Husheng, Zhao Yue, Alfred O. Mueck. Characteristics of obesity and glycolipid metabolism in polycystic ovary syndrome patients with diminished ovarian reserve[J]. Journal of Capital Medical University, 2018, 39(4): 505-511.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.04.005

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I4/505

References

[1] Sirmans S M, Pate K A. Epidemiology, diagnosis, and management of polycystic ovary syndrome[J]. Clin Epidemiol,2013,18(6):1-13.
[2] Tziomalos K, Dinas K. Obesity and outcome of assisted reproduction in patients with polycystic ovary syndrome[J]. Front Endocrinol:Lausanne, 2018,9:149.
[3] 刘伟,李圣贤.代谢紊乱与多囊卵巢综合征:挑战与机遇[J].中华内分泌代谢杂志,2017,33(12):1007-1011.
[4] 中华医学会妇产科学分会内分泌学组及指南专家组.多囊卵巢综合征中国诊疗指南[J].中华妇产科杂志,2018,53(1):2-6.
[5] Chun S. Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in korean women with polycystic ovary syndrome[J]. Clin Exp Reprod Med,2014,41(2):86-91.
[6] Zhao Y, Ruan X, Mueck A O. Clinical and laboratory indicators of polycystic ovary syndrome in Chinese Han nationality with different rotterdam criteria-based phenotypes[J].Gynecol Endocrinol,2016,32(2):151-156.
[7] Jin J,Ruan X,Hua L,et al. Prevalence of diminished ovarian reserve in Chinese women with polycystic ovary syndrome and sensitive diagnostic parameters[J]. Gynecol Endocrinol,2017, 33(9):694-697.
[8] 金婧,阮祥燕,华琳,等. 多囊卵巢综合征合并卵巢储备功能低下病人的内分泌特征[J]. 首都医科大学学报,2017,38(4):515-520.
[9] 金婧,阮祥燕,华琳,等.多囊卵巢综合征合并卵巢储备功能低下患者的发生现状[J].生殖医学杂志,2018,27(2):103-107.
[10] The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)[J]. Hum Reprod,2004, 19(1):41-47.
[11] 谢登菊. 肥胖型多囊卵巢综合征患者临床特征分析[J]. 实用医学杂志,2012,28(21):3613-3614.
[12] Haffner S M, Miettinen H, Stern M P. The homeostasis model in the san antonio heart study[J]. Diabetes Care, 1997, 20(7):1087.
[13] Lim S S, Davies M J, Norman R J, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome:a systematic review and meta-analysis[J]. Hum Reprod Update, 2012, 18(6):618-637.
[14] 熊英,徐克惠.细胞因子检测对卵巢储备功能的评价及临床意义[J].实用妇产科杂志,2013,29(9):649-651.
[15] Bleil M E, Gregorich S E, Adler N E,et al. Race/ethnic disparities in reproductive age:an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling women[J]. Fertil Steril,2014,101(1):199-207.
[16] 吕志文,谢雄娥. 多囊性卵巢综合征患者AMH水平与内分泌代谢异常的相关性研究[J].国际检验医学杂志,2017,38(20):2818-2820.
[17] 王丽萍,方春霞,蔡文伟,等.PCOS患者AMH水平与肥胖、睾酮水平、胰岛素抵抗的相关性分析[J].浙江医学,2016,38(16):1354-1357.
[18] Thomson R L, Buckley J D, Moran L J, et al. The effect of weight loss on anti-Müllerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment[J]. Hum Reprod, 2009, 24(8):1976-1981.
[19] Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited:an update on mechanisms and implications[J]. Endocr Rev, 2012, 33(6):981-1030.
[20] 钟兴明,孙秀红,韦相才,等. PCOS大鼠卵巢AMH表达与IR的相关性研究[J]. 中国免疫学杂志,2014,30(3):307-311.
[21] Feldman R A, O'Neill K, Butts S F, et al. Antimullerian hormone levels and cardiometabolic risk in young women with polycystic ovary syndrome[J]. Fertil Steril,2017,107(1):276-281.
[22] CagIar G S,KahyaogIu l,Pabuccu R,et al.Anti-Mullerjan hormone and insulin resistance in classic phenotype lean PCOS[J].Arch Gynecol Obste,2013,288(4):905-910.
[23] Fonseca H P,Brondi R S,Piovesan F X,et al.Anti-MulIerian hormone and insulin resistance in polycystic ovary syndrome[J]. Gynecol Endocrinol,2014,30(9):667-670.
[24] Li Y,Ma Y,Chen X,et al.Different diagnostic power of antiMullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism[J].J Assjsl Reprod Genet,2012,29(10):1147-1151.
[25] Cui Y, Shi Y, Cui L, et al. Age-specific serum antimullerian hormone levels in women with and without polycystic ovary syndrome[J]. Fertil Steril,2014,102(1):230-236.
[26] 王小霞,邓翠. PCOS患者血清AMH水平与胰岛素抵抗及雄激素的相关性研究[J]. 湖北民族学院学报:医学版,2017,34(2):8-10.
[27] De Leo V,la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome[J].Endocrine Rev,2011,24(5):633-667.
[28] Kiranmayee D, Kavya K, Himabindu Y, et al. Correlations between anthropometry and lipid profile in women with PCOS[J]. J Hum Reprod Sci,2017,10(3):167-172.
[29] 殷冬梅,阮祥燕,赵越,等. 北京地区多囊卵巢综合征病人内分泌代谢特征分析[J].首都医科大学学报,2017,38(4):498-503.
[30] Kumar A N, Naidu J N, Satyanarayana U,et al. Metabolic and endocrine characteristics of Indian women with polycystic ovary syndrome[J].Int J Fertil Steril,2016,10(1):22-28.
[31] Bilal M, Haseeb A, Rehman A. Relationship of polycystic ovarian syndrome with cardiovascular risk factors[J]. Diabetes Metab Syndr, 2018,12(3):375-380.
[32] 邹建平,陈颖,李圣贤,等. PCOS患者胰岛素抵抗和B细胞功能的改变及与体脂的关系[J].医学研究杂志,2017,46(11):124-127.
[33] Verit F F, Akyol H, Sakar M N. Low antimullerian hormone levels may be associated with cardiovascular risk markers in women with diminished ovarian reserve[J].Gynecol Endocrinol,2016,32(4):302-305.
[34] Verit F F, Keskin S, Omer B, et al. Is there any relationship between cardiovascular risk markers and young women with diminished ovarian reserve?[J]. Gynecol Endocrinol,2014,30(10):697-700.
[35] Bleil M E, Gregorich S E, McConnell D, et al. Does accelerated reproductive aging underlie premenopausal risk for cardiovascular disease?[J]. Menopause,2013,20(11):1139-1146.
[36] Tehrani F R, Erfani H, Cheraghi L, et al. Lipid profiles and ovarian reserve status:a longitudinal study[J]. Hum Reprod,2014,11:2522-2529.
[37] Zhu J, Wang J, Chen Y. Anti-Müllerian hormone levels in Chinese women younger than 30 years and 30 years or older and correlated biochemical indices[J]. Obstet Gynecol Surv,2017,72(1):33-38.